Search

Your search keyword '"Yosuke Togashi"' showing total 284 results

Search Constraints

Start Over You searched for: Author "Yosuke Togashi" Remove constraint Author: "Yosuke Togashi"
284 results on '"Yosuke Togashi"'

Search Results

1. Stem-like progenitor and terminally differentiated TFH-like CD4+ T cell exhaustion in the tumor microenvironment

2. Immunologic Significance of CD80/CD86 or Major Histocompatibility Complex-II Expression in Thymic Epithelial Tumors

4. Transcript-targeted analysis reveals isoform alterations and double-hop fusions in breast cancer

5. HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs

6. Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens

7. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma

8. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment

9. Clinical and immune profiling for cancer of unknown primary site

10. Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer

11. Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

12. Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

13. Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation

14. Outcome of Surgical Treatment for Metastatic Vertebra Bone Tumor in Advanced Lung Cancer

15. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.

16. Melanoma transition is frequently accompanied by a loss of cytoglobin expression in melanocytes: a novel expression site of cytoglobin.

17. High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects

18. Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity

19. Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens

20. Resistance to immune checkpoint inhibitors and the tumor microenvironment

22. Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration

24. Data from High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects

26. Table S7 from Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1

27. Supplementary Figure S6 from Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration

28. Supplementary Table S6. from Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration

29. Data from Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration

30. Supplementary Data from Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1

31. Data from Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1

32. Supplementary Figure S1 from Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC

33. Supplementary Table S1 from Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC

38. Supplementary Table 1 from Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer

40. A variety of ‘exhausted’ T cells in the tumor microenvironment

42. HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability

43. Supplementary Figure from Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer

44. Figure S11 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity

45. Figure S1 from Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)

46. Supplementary Figure Legend from EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

47. Supplementary Figure S3 from Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2

48. Data from Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2

50. Data from EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

Catalog

Books, media, physical & digital resources